PMID- 27859250
OWN - NLM
STAT- MEDLINE
DCOM- 20170515
LR  - 20220321
IS  - 1873-3468 (Electronic)
IS  - 0014-5793 (Linking)
VI  - 590
IP  - 24
DP  - 2016 Dec
TI  - Both bulk and cancer stem cell subpopulations in triple-negative breast cancer 
      are susceptible to Wnt, HDAC, and ERalpha coinhibition.
PG  - 4606-4616
LID - 10.1002/1873-3468.12496 [doi]
AB  - Development of targeted therapies for triple-negative breast cancer (TNBC, a more 
      aggressive subtype) is an unmet medical need. We analyzed data from 887 patients 
      with invasive breast cancer and observed that increased Wnt and histone 
      deacetylase (HDAC) activities are associated with estrogen receptor 1 (ESR1) and 
      progesterone receptor (PGR) repression, poor survival, and increased relapse. The 
      inverse correlation between Wnt signaling and repression of ESR1 and PGR 
      expression was found to be magnified in cancer stem cell (CSC) subpopulations in 
      TNBC cell lines. Cosuppression of Wnt, HDAC, and ESR1 using clinically relevant 
      low-dose inhibitors effectively repressed both bulk and CSC subpopulations and 
      converted CSCs to non-CSCs in TNBC cells without affecting MCF-10A mammary 
      epithelial cells.
CI  - (c) 2016 Federation of European Biochemical Societies.
FAU - Sulaiman, Andrew
AU  - Sulaiman A
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
FAU - Sulaiman, Brandon
AU  - Sulaiman B
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
FAU - Khouri, Lara
AU  - Khouri L
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
FAU - McGarry, Sarah
AU  - McGarry S
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
FAU - Nessim, Carolyn
AU  - Nessim C
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Canada.
FAU - Arnaout, Angel
AU  - Arnaout A
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Canada.
FAU - Li, Xuguang
AU  - Li X
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
AD  - Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, 
      Health Canada Sir Frederick G. Banting Research Centre, Ottawa, Canada.
FAU - Addison, Christina
AU  - Addison C
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Canada.
FAU - Dimitroulakos, Jim
AU  - Dimitroulakos J
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Canada.
FAU - Wang, Lisheng
AU  - Wang L
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, Canada.
AD  - Regenerative Medicine Program, Ottawa Hospital Research Institute, Canada.
AD  - Ottawa Institute of Systems Biology, University of Ottawa, Canada.
LA  - eng
PT  - Letter
DEP - 20161209
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD24 protein, human)
RN  - 0 (CD44 protein, human)
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Wnt Proteins)
RN  - 0 (beta Catenin)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.5.1.98 (Histone Deacetylases)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - CD24 Antigen/genetics/metabolism
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - Epithelial Cells/cytology/drug effects/metabolism
MH  - Estrogen Receptor alpha/*antagonists & inhibitors/genetics/metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histone Deacetylase Inhibitors/pharmacology
MH  - Histone Deacetylases/*genetics/metabolism
MH  - Humans
MH  - Hyaluronan Receptors/genetics/metabolism
MH  - Neoplastic Stem Cells/*drug effects/metabolism/pathology
MH  - RNA, Small Interfering/genetics/metabolism
MH  - Receptor, ErbB-2/deficiency/genetics
MH  - Receptors, Progesterone/deficiency/genetics
MH  - Signal Transduction
MH  - Survival Analysis
MH  - Tamoxifen/pharmacology
MH  - Triple Negative Breast Neoplasms/*genetics/metabolism/mortality/pathology
MH  - Valproic Acid/pharmacology
MH  - Wnt Proteins/*antagonists & inhibitors/genetics/metabolism
MH  - beta Catenin/antagonists & inhibitors/genetics/metabolism
OTO - NOTNLM
OT  - HDAC
OT  - TNBC
OT  - ESR1
OT  - Wnt
OT  - cancer stem cell
EDAT- 2016/11/20 06:00
MHDA- 2017/05/16 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2016/10/21 00:00 [revised]
PHST- 2016/10/31 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/05/16 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - 10.1002/1873-3468.12496 [doi]
PST - ppublish
SO  - FEBS Lett. 2016 Dec;590(24):4606-4616. doi: 10.1002/1873-3468.12496. Epub 2016 
      Dec 9.